Investec Sees Significantly Higher H1 Profit; Lifts FY22 Profit View - Quick Facts

Banking and wealth management group Investec Plc.(INVP.L) Thursday said its trading performance for the five months ended August 31 was substantially ahead of last year, and in line with the pre-COVID comparative period in 2019. The results were benefited by good growth in revenue and lower impairments.

For the six months ending September 30, the company expects basic earnings per share between 20.2 pence and 22.7 pence, up 110 percent to 136 percent from last year's 9.6 pence.

Adjusted earnings per share is expected between 21.5 pence and 24 pence, 92 percent to 114 percent higher than 11.2 pence a year ago.

Adjusted operating profit before tax is expected between 265 million pounds and 293 million pounds, or 86 percent to 106 percent ahead of last year's 142.5 million pounds.

The company plans to release interim results on November 18.

Looking ahead for fiscal 2022, the company expects to report adjusted earnings per share above the upper end of the 36 pence to 41 pence range guided in May, based on current business momentum.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT